Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Mainz BioMed NV

Mainz BioMed NV

BERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetic diagnostics company specializing in the early detection of cancer, today announced that members of its leadership team will participate in two major conferences in November and December 2022, Deutsches Eigenkapitalforum 2022 and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference.

German Equity Forum 2022
Date: November 28-30, 2022
Location: Frankfurt, Germany
Presentation: 9:30 a.m. CET, Tuesday, November 29, 2022
The Deutsche Eigenkapitalforum has become one of the most important capital market conferences on the subject of corporate finance in Europe.

To register for the event, please visit

Conference on medical and aesthetic dermatology, ophthalmology and medical technologies by Cantor Fitzgerald
Date: December 8, 2022
Location: Miami, Florida
Presentation: 10 a.m. EST, Thursday, December 8, 2022
Cantor Fitzgerald’s Medical and Aesthetic Dermatology, Ophthalmology and Medical Technology Conference will feature one-on-one meetings with leading companies in the medical and aesthetic dermatology, ophthalmology and medical technology industries, as well as key opinion leaders in the field of dermatology and ophthalmology.

To register for the event, please visit

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening diseases. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use diagnostic test for the early detection of colorectal cancer. ColoAlert is currently marketed in Europe and the United Arab Emirates with plans to begin its pivotal FDA clinical study in 2022 for US regulatory approval. Mainz Biomed’s portfolio of product candidates also includes PancAlert, an early detection test for pancreatic cancer based on real-time multiplex polymerase chain reaction (PCR)-based detection of molecular genetic biomarkers in stool samples. To learn more, visit or follow us on LinkedIn, Twitter and Facebook.

For media inquiries

In Europe:
MC Services SA
Anne Hennecke/Caroline Bergmann
+49 211 529252 20

In the USA:
Spectrum science
Melissa Laverty/Valerie Enes
+1 540 272 6465

For investor enquiries, please Contact

Forward-looking statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as ” anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook” and “project” and other similar expressions which predict or indicate future events or trends or which are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. Accordingly, caution should be exercised when relying on forward-looking statements. Due to known risks and unknown, actual results could differ materially from the Company’s expectations or projections. The following factors, among others, could cause the Actual results differ materially from those described in these forward-looking statements: (i) failure to achieve projected developments and related objectives; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or anticipated markets; and (iv) other risks and uncertainties described herein, as well as the risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the society. Additional information regarding these and other factors that may affect the Company’s expectations and projections is contained in its initial SEC filings, including its Annual Report on Form 20-F filed May 5. 2022. The Company’s filings with the SEC are publicly available on the SEC’s website at Any forward-looking statement we make in this press release is based solely on information currently available to Mainz Biomed and speaks only as of the date it is made. Mainz Biomed undertakes no obligation to update publicly any forward-looking statements, written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. required.

#Mainz #Biomed #Participate #Deutsche #Eigenkapitalforum #Cantor #Fitzgeralds #Medical #Aesthetic #Dermatology #Ophthalmology #MedTech #Conference

Leave a Comment

Your email address will not be published. Required fields are marked *